Pricing Log in Create free account

Arvinas, Inc. (ARVN) vs Relmada Therapeutics, Inc. (RLMD)

Arvinas, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Arvinas, Inc. and Relmada Therapeutics, Inc. are of similar size ($455.5M and $453.2M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −3.45%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Relmada Therapeutics, Inc. leads on 7 and Arvinas, Inc. on 6.

Valuation

Metric ARVN RLMD Biotechnology median
P/E n/m n/m 11.58
P/S 1.63 n/m 9.61
P/B 0.87 2.40 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA 3.32 n/m 0.72
EV/Sales (0.39) n/m 9.43
Earnings yield (2.22%) (21.66%) (32.28%)
Free cash flow yield (35.57%) (25.70%) (22.27%)

Profitability

Metric ARVN RLMD Biotechnology median
Gross margin 96.69% 0.00% 68.81%
Operating margin (12.13%) 0.00% 0.00%
Net margin (3.45%) 0.00% 0.00%
Free cash flow margin (58.05%) 0.00% 0.00%
Return on equity (1.76%) (55.66%) (50.30%)
Return on assets (1.31%) (51.57%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN RLMD Biotechnology median
Revenue growth (TTM) (11.85%) — 6.78%
EPS growth (last fiscal year) 58.84% 45.28% 29.88%
Revenue growth, 5-year CAGR 58.93% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARVN RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.39 29.52 4.74
Net debt to EBITDA 5.62 1.57 1.01

Dividend

Metric ARVN RLMD Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ARVN RLMD Biotechnology median
Market cap 453.16m 455.48m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack